An interventional study of Selective Laser trabeculoplasty in Glaucoma and Inflammatory Response, sponsored by CHU de Quebec-Universite Laval. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-29.
Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Treatment
The present study's main objective is to assess if there is a significant difference between either of the treatments frequently used in post-op, namely a topic cortisone-based treatment, an non-steroidal anti-inflammatory drug (NSAID) or simply a placebo, in order to gain the best long term (6 months) efficacy of the SLT.
The selective laser trabeculoplasty (SLT) is the laser treatment of choice for treating glaucoma. A There is however a controversy regarding the use of drops post-treatment. Indeed, some would prefer not to pharmacologically modulate the post-op inflammatory response which can be an integral part of the treatment by favouring the mobilisation of the macrophages which participate to the trabeculae "cleaning". Others will prefer to calm the inflammatory reaction and choose an anti-inflammatory drug (either steroidal or non-steroidal).
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 67 is close to the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →CHU de Quebec-Universite Laval is the lead sponsor of 134 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
A topic cortisone-based treatment
Procedure: Selective Laser trabeculoplasty
an non-steroidal anti-inflammatory drug
Procedure: Selective Laser trabeculoplasty
Pharmasciences DIN: 02229570
Procedure: Selective Laser trabeculoplasty
The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
Intraocular pressure in the treated eye
Time frame: 1 hour, 7 days, 1.5, 3 and 6 months
Side effects (include a slight uveitis, oculary discomfort and a spike in intraocular pressure in the immediate post-op period)
Time frame: 1 hour, 7 days, 1.5 months, 3 months and 6 months
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHU de Quebec-Universite Laval